Détail de l'auteur
Auteur G. J. DORE |
Documents disponibles écrits par cet auteur (22)
Ajouter le résultat à votre sélection Affiner la recherche
M. ALAVI ; J. GREBELY ; M. MICALLEF ; A. J. DUNLOP ; A. C. BALCOMB ; C. A. DAY ; C. TRELOAR ; N. BATH ; P. S. HABER ; G. J. DORE | 2013
Dans Clinical Infectious Diseases (Vol.57, Suppl.2, August 2013) Article : PériodiqueBACKGROUND: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who inject drugs (PWID). HCV assessment and treatment was evaluated through an innovative model for the provision of HCV care among PWID with chronic [...]S. LARNEY ; J. GREBELY ; M. HICKMAN ; D. DE ANGELIS ; G. J. DORE ; L. DEGENHARDT | 2015
Dans International Journal of Drug Policy (Vol.26, n°10, October 2015) Article : PériodiqueThere is considerable interest in determining the impact that increased uptake of treatment for hepatitis C virus (HCV) infection will have on the burden of HCV among people who inject drugs (PWID). An understanding of the size of the population[...]J. GREBELY ; G. J. DORE ; S. MORIN ; J. K. ROCKSTROH ; M. B. KLEIN | 2017
Dans Journal of the International AIDS Society (Vol.20, n°22146, August 2017) Article : PériodiqueINTRODUCTION: Globally, there is a considerable burden of HCV and HIV infections among people who inject drugs (PWID) and transmission of both infections continues. Needle and syringe programme (NSP) and opioid substitution therapy (OST) coverag[...]L. DEGENHARDT ; P. WEBB ; S. COLLEDGE-FRISBY ; J. IRELAND ; A. WHEELER ; S. OTTAVIANO ; A. WILLING ; A. KAIROUZ ; E. B. CUNNINGHAM ; B. HAJARIZADEH ; J. LEUNG ; L. T. TRAN ; O. PRICE ; A. PEACOCK ; P. VICKERMAN ; M. FARRELL ; G. J. DORE ; M. HICKMAN ; J. GREBELY | 2023
Dans Lancet Global Health (The) (Vol.11, n°5, May 2023) Article : PériodiqueBACKGROUND: People who inject drugs are exposed to various and changing risk environments and are at risk of multiple harms related to injecting drug use (IDU). We aimed to undertake a global systematic review of the prevalence of IDU, key IDU-r[...]J. A. KWON ; J. ANDERSON ; C. C. KERR ; H. H. THEIN ; L. ZHANG ; J. IVERSEN ; G. J. DORE ; J. M. KALDOR ; M. G. LAW ; L. MAHER ; D. P. WILSON | 2012
Dans AIDS (Vol.26, n°17, November 2012) Article : PériodiqueOBJECTIVE: To evaluate the impact and cost-effectiveness of needle-syringe programs (NSPs) with respect to HIV and hepatitis C virus (HCV) infections among Australian injecting drug users (IDUs). DESIGN/METHODS: A health economic analysis was [...]S. LARNEY ; M. HICKMAN ; R. GUY ; J. GREBELY ; G. J. DORE ; R. T. GRAY ; C. A. DAY ; J. KIMBER ; L. DEGENHARDT | 2017
Dans BMC Public Health (Vol.17, n°757, 2017) Article : PériodiqueBackground: Injecting drug use is associated with considerable morbidity and mortality. Estimates of the size of the population of people who inject drugs are critical to inform service planning and estimate disease burden due to injecting drug [...]International Journal of Drug Policy, Vol.26, n°10 - October 2015 - Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs
J. GREBELY, Éditeur scientifique ; P. BRUGGMANN, Éditeur scientifique ; C. TRELOAR, Éditeur scientifique ; G. J. DORE, Éditeur scientifique | 2015
Bulletin : PériodiqueJ. GREBELY ; P. BRUGGMANN ; C. TRELOAR ; J. BYRNE ; T. RHODES ; G. J. DORE | 2015
Dans International Journal of Drug Policy (Vol.26, n°10, October 2015) Article : PériodiqueS. COLLEDGE-FRISBY ; S. OTTAVIANO ; P. WEBB ; J. GREBELY ; A. WHEELER ; E. B. CUNNINGHAM ; B. HAJARIZADEH ; J. LEUNG ; A. PEACOCK ; P. VICKERMAN ; M. FARRELL ; G. J. DORE ; M. HICKMAN ; L. DEGENHARDT | 2023
Dans Lancet Global Health (The) (Vol.11, n°5, May 2023) Article : PériodiqueBACKGROUND: Harm reduction and treatment programmes are essential for reducing harms for people who inject drugs (PWID). We aimed to update estimates from a 2017 review of global coverage of needle and syringe exchange programmes (NSPs), opioid [...]J. GREBELY ; S. LARNEY ; A. PEACOCK ; S. COLLEDGE ; J. LEUNG ; M. HICKMAN ; P. VICKERMAN ; S. BLACH ; E. B. CUNNINGHAM ; K. DUMCHEV ; M. LYNSKEY ; J. STONE ; A. TRICKEY ; H. RAZAVI ; R. P. MATTICK ; M. FARRELL ; G. J. DORE ; L. DEGENHARDT | 2019
Dans Addiction (Vol.114, n°1, January 2019) Article : PériodiqueBACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with[...]HALLINAN R. ; A. BYRNE ; G. J. DORE | 2007
Dans Drug and Alcohol Review (Vol.26 n°4, 2007) Article : PériodiqueENGLISH : While harm reduction advocates, policy makers and practitioners have a right to be proud of the impact of interventions such as needle and syringe programmes on HIV risk, we can be less sanguine about the ongoing high levels of HCV t[...]FRANÇAIS : La cohorte étudiée a été recrutée parmi les patients d'un centre de prévention et traitement du VIH/Sida et autres maladies infectieuses à Sydney, qui accueille des usagers de drogues par voie injectable et des prostitués depuis 1987[...]E. B. CUNNINGHAM ; A. WHEELER ; B. HAJARIZADEH ; C. E. FRENCH ; R. ROCHE ; A. D. MARSHALL ; G. FONTAINE ; A. CONWAY ; S. BAJIS ; B. M. VALENCIA ; J. PRESSEAU ; J. W. WARD ; L. DEGENHARDT ; G. J. DORE ; M. HICKMAN ; P. VICKERMAN ; J. GREBELY | 2023
Dans International Journal of Drug Policy (Vol.111, January 2023) Article : PériodiqueBackground: With the advent of direct acting antiviral (DAA) therapies for the treatment of hepatitis C virus (HCV), the World Health Organization recommended a goal to eliminate HCV as a public health threat globally by 2030. With the majority [...]S. BAJIS ; G. J. DORE ; B. HAJARIZADEH ; E. B. CUNNINGHAM ; L. MAHER ; J. GREBELY | 2017
Dans International Journal of Drug Policy (Vol.47, September 2017) Article : PériodiqueBackground: The burden of hepatitis C virus (HCV) infection is escalating among people who inject drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic review was to evaluate the effectiveness of interventions to[...]J. GREBELY ; P. BRUGGMANN ; M. BACKMUND ; G. J. DORE | 2013
Dans Clinical Infectious Diseases (Vol.57, Suppl.2, August 2013) Article : PériodiqueThe majority of hepatitis C virus (HCV) occurs among people who inject drugs (PWID), and the burden of HCV-related liver disease is still increasing. HCV treatment is safe and effective among PWID, and international guidelines encourage HCV trea[...]